|
Market Closed -
Nasdaq
16:00:00 2026-10-23 EDT
|
5-day change | 1st Jan Change | ||
| 0.5177 USD | -4.41% |
|
-11.38% | -39.31% |
| 10-14 | Ladenburg Thalmann Initiates Aprea Therapeutics at Buy With $2 Price Target | MT |
| 08-28 | Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs | CI |
Company Valuation: Aprea Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 17.54 | 17.56 | 17.88 | 5.966 | 6.518 | - | - |
| Change | - | 0.11% | 1.81% | -66.64% | 9.26% | - | - |
| Enterprise Value (EV) | 17.54 | 17.56 | 17.88 | 5.966 | 6.518 | 6.518 | 6.518 |
| Change | - | 0.11% | 1.81% | -66.64% | 9.26% | 0% | 0% |
| P/E | -0.1x | -1.19x | -1.4x | -0.44x | -1.55x | -1.43x | -1.49x |
| PBR | - | - | - | - | - | - | - |
| PEG | -0x | 0x | 0x | 0x | 0x | -0.17x | 0.34x |
| Capitalization / Revenue | - | 30.1x | 11.9x | 20.9x | - | - | - |
| EV / Revenue | - | 0x | 0x | 0x | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0.38x | -0.28x | -0.21x |
| EV / FCF | -0x | - | - | - | -0.4x | -0.24x | -0.17x |
| FCF Yield | -652% | - | - | - | -249% | -417% | -586% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -67.99 | -3.95 | -2.35 | -1.93 | -0.335 | -0.3625 | -0.3467 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | 0.5832 | 1.503 | 0.2858 | - | - | - |
| EBITDA | -113.4 | -15.46 | -14.3 | - | - | - | - |
| EBIT 1 | -113.4 | -15.47 | -14.32 | -13.23 | -17.03 | -22.92 | -30.35 |
| Net income 1 | -112.7 | -14.29 | -12.96 | -12.6 | -16.07 | -22.52 | -27.38 |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 6.6200 | 4.7000 | 3.2900 | 0.8530 | 0.5177 | 0.5177 | 0.5177 |
| Nbr of stocks (in thousands) | 2,650 | 3,737 | 5,435 | 6,994 | 12,591 | - | - |
| Announcement Date | 3/30/23 | 3/26/24 | 3/25/25 | 3/16/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.62x | - | - | - | 6.82M | |
| 18.38x | 6.48x | 12.88x | 1.62% | 63.29B | |
| 30.22x | 7.94x | 26.49x | 0.05% | 54.89B | |
| 36.58x | 6.5x | 19.41x | 0.88% | 53.28B | |
| 35.46x | 3.44x | 14.83x | -.--% | 45.81B | |
| 50.32x | 5.82x | 31.95x | -.--% | 43.46B | |
| -19.48x | 188.5x | -20.74x | -.--% | 40.23B | |
| 29.02x | 8.23x | 21.28x | 0.37% | 33.45B | |
| 27.38x | 5.77x | 14.95x | -.--% | 23.7B | |
| 32.79x | 5.99x | 20.16x | -.--% | 23.76B | |
| Average | 23.91x | 26.52x | 15.69x | 0.32% | 38.19B | |
| Weighted average by Cap. | 26.70x | 25.51x | 15.93x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- APRE Stock
- Valuation Aprea Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
